Gastrointestinal cancer accounts for 3 million new cancer cases and more than 2 million cancer deaths annually. It represents a broad group of cancer of the alimentary tract, ranging from the esophagus, stomach, colorectal, pancreatobiliary and liver. There is an important need to continue educating physicians on the risk factors, symptoms, diagnosis and both medical and surgical treatment options for gastrointestinal cancer. As well as for frequent evaluations and close communication between medical oncologists, radiologists, radiation oncologist, surgeons, and patients to develop a treatment startegy in multidisciplinary setting to improve patient outcomes.
To Register for this event, please use the following link:
Dates and Times
Start: 9/23/2017 7:30 AM
End: 9/23/2017 3:00 PM
- Discuss and identify potential cancer patients who could benefit from immunotherapy and review the role of MSI, PD-1, PD-L1, and other biomarkers.
- Identify new targeted and systemic therapies in the treatment of gastric, colorectal, hepatobiliary, pancreatic cancer and neuroendocrine cancer with the focus on newly approved FDA agents.
- Explore novel genomic studies in diagnosis and treatment of gastrointestinal cancers.
- Discuss strategies to improve screening options and treatment for liver cancer and treatment options to eradicate hepatitis C.
- Engage physicians and healthcare workers to best clinical practice in the treatment of gastric, hepatobiliary, colorectal, pancreatic, carcinoid and other GI cancers.
Hyatt Regency Long Island
1717 Motor Parkway
Hauppauge, NY 11788
The School of Medicine, State University of New York at Stony Brook, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The School of Medicine, State University of New York at Stony Brook designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credit(s) ™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.